首页 > 资讯    /    正文

Kyung-Ah Kim Named as President and Chief Executive Officer of Samsung Bioepis

First time in Samsung's history to name a non-founder female Chief Executive Officer

INCHEON, South Korea, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that Kyung-Ah Kim, who has been serving as Executive Vice President and Development Division Leader, has been named as President and Chief Executive Officer of Samsung Bioepis. Kim will succeed Christopher Hansung Ko, who has been appointed to lead Samsung Future Business Division.

Kim, a veteran scientist with more than 20 years of experience in biologic development, has been serving as Development Division Leader since December 2021, overseeing all of Samsung Bioepis' product development cycle across various therapeutic areas. Since joining Samsung Bioepis in December 2015, she has been serving various leadership posts within Development Division. Prior to joining Samsung Bioepis, Kim worked as Principal Scientist and later as Vice President at Samsung Advanced Institute of Technology (SAIT) leading Biotherapeutics Group focusing on development of antibody therapeutics targeting oncology. Before joining SAIT, she worked as a scientist/head of cell biology at multiple biopharmaceutical companies, leading various projects on development of therapeutic agents, including genetic sequencing and profiling, development of drug screening assays, pre-clinical assessment, pharmacological assessment, and functional assessment of antibodies.

Kim holds a Ph.D in neurotoxicology from The Johns Hopkins University where she established signal transduction pathway, specifically in the learning impairment caused by genetic perturbation in lead poisoning.

About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – XLinkedIn.

MEDIA CONTACT
Anna Nayun Kim, nayun86.kim@samsung.com
Yoon Kim, yoon1.kim@samsung.com

最新文章

“2025东西部协作帮扶促消费暨糯食产业招商会”在贵州贞丰糯食之乡举行 休斯顿大学视光学院Mark A.Bullimore教授:儿童青少年近视防控,每一个屈光度都重要 杭州天目山医院耳鼻喉科:精准诊疗,守护呼吸与听觉的“门户” 坚守人民立场,用电影阐述生生不息的人民史诗——康红立导演如何用真情丈量人民足迹,用电影弘扬时代精神 ​深圳网站建设公司甄选指南:368 家上市公司首选沙漠风的深度解密 聚焦游戏测试、副玩法和AI驱动,Meta赋能游戏出海增长新纪元

Copyright © 2024 商圈 All Rights Reserved.

本站部分内容来源于用户投稿,内容相关Q:230098551